|1.||Sporn, Michael B: 18 articles (07/2015 - 01/2002)|
|2.||Gautam, Subhash C: 17 articles (12/2015 - 09/2007)|
|3.||Gao, Xiaohua: 17 articles (12/2015 - 09/2007)|
|4.||Deeb, Dorrah: 17 articles (12/2015 - 09/2007)|
|5.||Liu, Yongbo: 11 articles (12/2015 - 09/2007)|
|6.||Andreeff, Michael: 11 articles (11/2014 - 01/2002)|
|7.||Konopleva, Marina: 11 articles (08/2014 - 01/2002)|
|8.||Dulchavsky, Scott A: 10 articles (11/2011 - 09/2007)|
|9.||Williams, Charlotte R: 9 articles (07/2015 - 09/2004)|
|10.||Arbab, Ali S: 9 articles (01/2013 - 02/2010)|
03/15/2010 - "CDDO-Me abrogated the immune suppressive effect of MDSCs and improved immune responses in tumor-bearing mice and cancer patients. "
03/15/2010 - "Treatment of tumor-bearing mice with CDDO-Me did not affect the proportion of MDSCs in the spleens but eliminated their suppressive activity. "
01/01/2014 - "In a Phase I trial in cancer patients, CDDO-Me was found to have a slow and saturable oral absorption, a relatively long terminal phase half-life (39 hours at 900 mg/day), nonlinearity (dose-dependent) at high doses (600-1,300 mg/day), and high interpatient variability. "
04/15/2008 - "The C-28 methyl ester of the oleane triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO-Me) induces apoptosis of human cancer cells by disrupting redox balance and is in clinical trials. "
12/01/2015 - "These preclinical data demonstrate the potential of CDDO-Me for treating primary PDAC tumors and for preventing relapse/recurrence through the destruction of residual disease. "
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/2011 - "In the present study, we examined the efficacy of CDDO-Me in preventing the development and progression of prostate cancer in the transgenic adenocarinoma of the mouse prostate (TRAMP) model. "
01/06/2012 - "Present studies show that Akt plays a critical role in the response of prostate cancer cells to CDDO-Me. "
06/01/2009 - "This study demonstrated potent antitumor activity of CDDO-Me against prostate cancer cells both in vitro and in vivo. "
09/01/2007 - "These studies provide a rationale for clinical evaluation of CDDO-Me as adjuvant therapy for treatment of advanced and fatal form of prostate cancer."
01/01/2012 - "We investigated the role of hTERT in mediating the anticancer activity of CDDO-Me in prostate cancer cells in vitro and in vivo. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
03/15/2010 - "Treatment of pancreatic cancer patients with CDDO-Me did not affect the number of MDSCs in peripheral blood but significantly improved the immune response. "
01/01/2012 - "Micromolar concentrations of CDDO-Me inhibited proliferation and induced apoptosis in MiaPaCa-2 and Panc-1 pancreatic cancer cells. "
01/01/2012 - "Inhibition of cell proliferation and induction of apoptosis by CDDO-Me in pancreatic cancer cells is ROS-dependent."
12/01/2010 - "CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations. "
12/01/2010 - "CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer."
|4.||Kidney Diseases (Kidney Disease)
01/01/2014 - "As a multifunctional agent, CDDO-Me has improved the renal function in patients with chronic kidney disease associated with type 2 diabetes. "
05/01/2013 - "A recent clinical trial in patients with chronic kidney disease (CKD) and diabetic nephropathy demonstrated that bardoxolone methyl (CDDO-ME) increases estimated glomerular filtration rate (eGFR) by an unknown mechanism. "
01/01/2013 - "CDDO-Me has been shown to exert potent anti-inflammatory activity for chronic kidney disease and antitumor activity for several tumors, including melanoma, in early clinical trials. "
01/01/2014 - "CDDO-Me has been used for the treatment of chronic kidney disease, cancer (including leukemia and solid tumors), and other diseases. "
08/28/2014 - "For example, CDDO-me (bardoxolone methyl) was investigated in clinical trials for the treatment of acute kidney disease, and dimethyl fumarate, recently approved for reducing relapse rate in multiple sclerosis, is a potent Nrf2 inducer. "
|5.||Breast Neoplasms (Breast Cancer)
08/28/2015 - "In this study, we show that treatment with CDDO-Me induces progressive endoplasmic reticulum (ER)-derived vacuolation in various breast cancer cells and ultimately kills these cells by inducing apoptosis. "
08/28/2015 - "Taken together, our results show that ER-derived vacuolation via Ca2+ influx and ROS generation as well as caspase activation via c-FLIPL downregulation are responsible for the potent anticancer effects of CDDO-Me on breast cancer cells. "
08/28/2015 - "Ca2+ influx-mediated dilation of the endoplasmic reticulum and c-FLIPL downregulation trigger CDDO-Me-induced apoptosis in breast cancer cells."
01/01/2014 - "In the present series of experiments, we determined if CDDO-Me can be used as a radioprotector in normal non-cancerous human lung and breast epithelial cells, in comparison to lung and breast cancer cell lines. "
01/01/2012 - "These results suggest that CDDO-Me has the potential to prevent BRCA1-mutated breast cancer."
|1.||Interleukin-6 (Interleukin 6)
|4.||Interleukin-10 (Interleukin 10)
|7.||Transforming Growth Factors (Transforming Growth Factor)
|8.||Messenger RNA (mRNA)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)